Mainly because people who have the APOE e4 gene variant appear to have a increased threat of significant complications, the FDA recommends getting tested with the gene variant before beginning treatment with lecanemab or donanemab. Concerning pharmacological interventions, a few guidelines advise no pharmacologic intervention. The use of cholinesterase inhibitors https://cashvvtvw.look4blog.com/72641673/neuropsychological-testing-for-dementia-near-me-can-be-fun-for-anyone